Session Title: AMD I
Session Date/Time: Friday 12/09/2014 | 08:00-10:00
Paper Time: 09:12
Venue: Boulevard C
First Author: : J.Mones SPAIN
Co Author(s): :
The ForeseeHome device has been validated in a prospective clinical trial for early detection of neovascular age-related macular degeneration (AMD). The purpose of this presentation is to demonstrate the ability of the technology to detect CNV in extremely early stages in real life.
A retrospective review of cases in which neovascular AMD was detected by the ForeseeHome device, including registration and evaluation of visual field defects maps generated by the device vs. FA and OCT imaging.
Cases in which early CNV in AMD was detected by the ForeseeHome device were examined. In all cases CNV features on FA and OCT were minimal (but yet detectable), visual acuity was excellent and a good match of the visual field defect maps to the other imaging modalities was observed.
The ForeseeHome device detects neovascular AMD at a very early stage and generates visual field metamorphospia maps. These visual field defect maps may provide helpful information facilitating the identification of the lesion by other modalities such as FA and OCT, or on at least one of these modalities, prior to appearance on both.